Literature DB >> 7533560

Growth factor targeted and conventional therapy of breast cancer.

A Wellstein1.   

Abstract

Sustained breast cancer growth and metastasis requires paracrine signals between the tumor cells and the normal surrounding host tissue. One crucial function of these signals is to recruit endothelial cells and thus new blood vessels for the nourishment of the expanding tumor mass. This proliferation and migration of endothelial cells in the vicinity of progressing tumors contrasts with the extremely low turn-over rate of endothelial cells in the healthy adult. A blockade of tumor-induced endothelial cell proliferation should inhibit tumor growth and potentially metastasis with only few adverse effects. Different therapeutic approaches that take advantage of this situation are discussed with respect to their interaction with conventional therapies of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7533560     DOI: 10.1007/bf00666148

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  58 in total

Review 1.  Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions.

Authors:  R Clarke; R B Dickson; M E Lippman
Journal:  Crit Rev Oncol Hematol       Date:  1992-01       Impact factor: 6.312

2.  Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent.

Authors:  M Kusaka; K Sudo; T Fujita; S Marui; F Itoh; D Ingber; J Folkman
Journal:  Biochem Biophys Res Commun       Date:  1991-02-14       Impact factor: 3.575

3.  Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation.

Authors:  A C Rapraeger; A Krufka; B B Olwin
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

4.  Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals.

Authors:  G Zugmaier; M E Lippman; A Wellstein
Journal:  J Natl Cancer Inst       Date:  1992-11-18       Impact factor: 13.506

Review 5.  Growth factors in development, transformation, and tumorigenesis.

Authors:  M Cross; T M Dexter
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

6.  Localization of the inhibitory site(s) of pentosan polysulphate in blood coagulation.

Authors:  R Wagenvoord; H Hendrix; C Soria; H C Hemker
Journal:  Thromb Haemost       Date:  1988-10-31       Impact factor: 5.249

7.  Multihormonal regulation of insulin-like growth factor-I-related protein in MCF-7 human breast cancer cells.

Authors:  K K Huff; C Knabbe; R Lindsey; D Kaufman; D Bronzert; M E Lippman; R B Dickson
Journal:  Mol Endocrinol       Date:  1988-03

8.  Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma.

Authors:  J Kandel; E Bossy-Wetzel; F Radvanyi; M Klagsbrun; J Folkman; D Hanahan
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

9.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

Authors:  A Yayon; M Klagsbrun; J D Esko; P Leder; D M Ornitz
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

10.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.

Authors:  E R Horak; R Leek; N Klenk; S LeJeune; K Smith; N Stuart; M Greenall; K Stepniewska; A L Harris
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

View more
  2 in total

Review 1.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

2.  Prognostic value of epidermal growth factor expression in breast cancer.

Authors:  R Pirinen; P Lipponen; S Aaltomaa; K Syrjänen
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.